GemOx-Based Combination Shows Improved Outcomes in Patients With R/R DLBCL

Key Clinical Summary

• Epcoritamab plus gemcitabine and oxaliplatin (Epcor+GemOx) significantly improved response rates vs rituximab plus GemOx (R-GemOx) in transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
• Indirect comparisons showed higher complete response rates and longer progression-free and overall survival with Epcor+GemOx.
• Findings support incorporating epcoritamab-based regimens into treatment pathways for high-risk, transplant-ineligible populations.

Epcor+GemOx demonstrated superior efficacy compared with R-GemOx in transplant-ineligible patients with R/R DLBCL, according to an indirect treatment comparison using clinical trial and real-world data.

Study Findings

The analysis compared individual patient data from EPCORE NHL-2 Arm 5 with real-world and published datasets using matching-adjusted indirect comparison (MAIC) and inverse probability of treatment weighting (IPTW). Outcomes included objective response rate (ORR), complete response (CR), progression-free survival (PFS), and overall survival (OS).

In the MAIC analysis, Epcor+GemOx achieved an ORR of 86.8% vs 38.3% with R-GemOx (relative risk [RR], 2.27; 95% CI, 1.76-2.93; P < .0001). CR rates were also higher at 71.2% vs 32.7% (RR, 2.18; 95% CI, 1.61-2.96; P < .0001). Median PFS was 26.7 months compared with 4.8 months (hazard ratio [HR], 0.38; 95% CI, 0.22-0.67; P < .001). Median OS was not reached with Epcor+GemOx vs 10.0 months for R-GemOx (HR, 0.54; P = .05).

Findings from the IPTW analysis were consistent. ORR was 88.5% with Epcor+GemOx vs 35.6% with R-GemOx (RR, 2.48; P < .0001), and CR rates were 63.9% vs 10.2% (RR, 6.25; P < .0001). Median PFS was 11.2 months vs 2.4 months (HR, 0.23; P < .001), and median OS was 21.6 months vs 8.3 months (HR, 0.47; P = .002).

Despite differences in baseline characteristics—including higher rates of refractory disease and adverse prognostic features in the Epcor+GemOx cohort—the treatment benefit remained consistent across analyses.

Implications for Transplant-Ineligible DLBCL Treatment Strategies

These findings are particularly relevant for transplant-ineligible patients with R/R DLBCL, a population with historically poor outcomes and limited treatment options. The substantial improvements in response rates and survival metrics suggest that Epcor+GemOx may address a significant unmet need.

From a managed care and payer perspective, therapies that improve durability of response and extend survival may influence treatment sequencing and value-based care decisions. The consistent benefit observed across both clinical trial and real-world comparisons strengthens the evidence base for epcoritamab in routine practice.

Additionally, the robustness of outcomes despite inclusion of patients with aggressive disease and refractory status highlights the regimen’s potential applicability across heterogeneous populations. Incorporating such therapies into treatment algorithms could shift standards of care and improve long-term disease control.

Author Insights on Epcoritamab’s Clinical Benefit

The analysis emphasized that Epcor+GemOx demonstrated statistically significant clinical benefits across key endpoints, including response and survival outcomes. The authors noted that these benefits persisted even after adjusting for differences in prognostic factors, underscoring the regimen’s effectiveness in a challenging and diverse patient population with limited therapeutic options.

Epcoritamab-Based Regimens Signal Shift in DLBCL Care

Epcoritamab plus GemOx significantly outperformed R-GemOx in indirect comparisons for transplant-ineligible R/R DLBCL. These results support broader integration of epcoritamab-based regimens to improve outcomes in a high-risk population with substantial unmet clinical need.

Reference

Munoz J, Rosenthal A, Ip A, et al. Epcoritamab plus gemcitabine and oxaliplatin versus rituximab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large b-cell lymphoma: a match-adjusted comparative analysis. Clin Lymphoma Myeloma Leuk. 2026;26(2):e283-e291. doi:10.1016/j.clml.2025.10.010